Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD1 | P21728 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015222 | 1.00 | DRD2 (0.46) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL383952 | 0.98 | DRD2 (0.44) | DRD2DRD1DRD4PNMTDRD3 | |
| Hydrochloric Acid SCHEMBL3772707 | 0.98 | DRD2 (0.44) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL29514775 | 0.82 | DRD2 (0.62) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL1017452 | 0.82 | DRD2 (0.62) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL470826 | 0.82 | PNMT (0.66) | DRD2DRD1DRD4PNMTDRD3 | |
| Hydrochloric Acid SCHEMBL2675120 | 0.81 | PNMT (0.63) | DRD2DRD1DRD4PNMTDRD3 | |
| Hydrochloric Acid SCHEMBL31336072 | 0.81 | DRD2 (0.61) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL587893 | 0.81 | DRD2 (0.61) | DRD2DRD1DRD4PNMTDRD3 | |
| Hydrochloric Acid SCHEMBL30955057 | 0.81 | PNMT (0.63) | DRD2DRD1DRD4PNMTDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930493-A | (R) - (1- ([ 1,1' -biphenyl ] -4-yl) -3-hydroxypropyl-2-yl) carbamic acid tert-butyl ester intermediate and preparation method and application thereof | 江苏科本药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-1013274-B | Process for preparing cephalosporin derivatives | BANYU PHARMA CO LTD (JP) | 1991-07-24 | — | — | CN | claimed |
| CN-85109769-A | The preparation of cephalosporins derivatives and application | — | 1986-12-17 | — | — | CN | claimed |
| EP-0186187-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-02 | — | — | EP | claimed |
| CN-119930493-A | (R) - (1- ([ 1,1' -biphenyl ] -4-yl) -3-hydroxypropyl-2-yl) carbamic acid tert-butyl ester intermediate and preparation method and application thereof | 江苏科本药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-114920911-B | Method for producing polyisothiaindene conductive polymer | 株式会社力森诺科 | 2024-05-03 | — | — | CN | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| CN-116391129-A | Target binding assays for RAS proteins | 普罗美加公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023070605-A1 | METHODS OF PREPARING 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS | TREVENA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| CN-1013274-B | Process for preparing cephalosporin derivatives | BANYU PHARMA CO LTD (JP) | 1991-07-24 | — | — | CN | disclosed |
| US-4677100-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-06-30 | — | — | US | disclosed |
| CN-85109769-A | The preparation of cephalosporins derivatives and application | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0186187-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | DRD2 4709/4885DRD1 4805/4885DRD4 4843/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | DRD2 808/4885DRD1 1130/4885DRD4 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.